Roche takes the Tim-3 battle to Novartis
The Swiss group has likely been paying attention to industry developments as BCMA and CD40 go out, while Covid-19 and Tim-3 move up.
Clearside’s long-acting eye project shows promise
But data are early, and other groups are also developing less frequent injections for wet AMD.
Nightstar becomes nightmare, but Biogen has bigger fish to fry
A second clinical failure means that Biogen threw away $877m, but this sum will today be seen as little more than a rounding error.
Adverum halt raises more gene therapy questions
A serious adverse event puts ADVM-022’s future in doubt, and it could hurt other eye disease gene therapy players too.
Gene therapy clinical holds take centre stage
An analysis of company disclosures reveals a sharp rise in US FDA-imposed halts on clinical work involving gene therapies.
Shire dodges pricing questions as lanadelumab’s big day nears
Shire's big pipeline hope, lanadelumab, should get approved soon – but will sales live up to expectations?